about
Molecular underpinnings of corneal angiogenesis: advances over the past decadeThe cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisThe era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapyVEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulationAnti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.KLF4 Promotes Angiogenesis by Activating VEGF Signaling in Human Retinal Microvascular Endothelial Cells.Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyureaVEGF released from a fibrin biomatrix increases VEGFR-2 expression and improves early outcome after ischaemia-reperfusion injury.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction.The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell lineRequirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesisDifferential function and regulation of orphan nuclear receptor TR3 isoforms in endothelial cells.Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapyEctodomain cleavage of FLT1 regulates receptor activation and function and is not required for its downstream intracellular cleavage.Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy.A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS.A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P.Modulation of VEGF receptor 2 signaling by protein phosphatases.Nucleoside diphosphate kinase B regulates angiogenic responses in the endothelium via caveolae formation and c-Src-mediated caveolin-1 phosphorylation.Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers.VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma.VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis.Therapeutic approaches for corneal neovascularization.Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model.Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.Glutamate Neonatal Excitotoxicity Modifies VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 Protein Expression Profiles During Postnatal Development of the Cerebral Cortex and Hippocampus of Male Rats.Vascular endothelial growth factor: An important molecular target of curcumin.Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol.Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists.A Novel Peptide Derived From Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization.Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells.Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.
P2860
Q26747539-54F58694-C14E-450B-B4FD-4CF88D675147Q26796921-F12A128C-A1D6-4E24-B0DB-20A69580E8B1Q28067341-57B8B3C7-294A-4089-94DB-1833CE138C1FQ30275233-F9384117-08DC-4230-8556-63B776107C98Q34193079-A2F3704C-2708-4CBC-ACAA-633C7AA0895BQ35580483-093B6B07-850A-4FCD-A945-446F0573C1FDQ35633420-D8E02324-EE22-4CD0-A98D-051FC4820EE0Q35663864-8F40EF59-1B29-4E44-B1D3-2047A7270959Q35669858-273960CA-83B3-47EE-8491-A04213FEB6F9Q35896387-82B8EBDD-680B-4C04-935F-6970E4DDB94CQ36113481-14D21E3D-CF10-4A61-98CA-C50D810830CEQ36213528-9722A908-8F56-45A4-9D5A-86A0F977267EQ36225028-995402FC-927D-4D7D-BF08-157E578B1EB8Q36363357-B961D9A3-0097-4D1E-8117-23378B640B6DQ36414440-ECC3D50D-722F-464D-916F-2FB996C3C9ACQ36814082-F956C6AE-70B4-4A39-A2ED-5C9C632B8316Q36821570-3BD18465-FA46-4465-AAD8-29A07666EB40Q36932603-BD8648F7-F1C6-4A9C-BF52-BCFAD506D1F6Q37260920-9FCA5CC0-AE4F-49B8-A1BD-C26F6B538BCCQ38307997-028D7BCB-5721-4E05-BBD6-C87A2FDF54FCQ38710512-E58D31CD-48C1-4352-92C9-161DC56F9459Q38801662-BB0306DD-6C91-4460-A939-826FA8F4E0E3Q38843251-F16A9675-B25B-4AA9-8175-F31DF9F364EAQ39020269-63110D63-8269-4B57-BAEE-E92EF81B48F3Q39389673-3776D2EB-9915-4692-ABF9-80DB373AC66AQ40097630-66662769-203A-415F-8C97-E46DA2E7BA50Q41083020-73AADB8D-99DF-4DA6-84B1-ED7D0D7AE96CQ42271421-6E5041A9-FBD8-40A9-B2DB-1B8806D7E552Q47143268-61F72C30-508C-47BE-827A-6E13FB6D94C5Q47157253-CD243A10-ECD4-4D89-8C6D-07F79B10F306Q47203673-69AEB1D7-BD8F-4CDB-B335-3458583E403BQ47386049-127E4F57-AB87-4E2C-8FBF-7602AAF21435Q48014497-A89FA25B-D95E-40BF-A94A-B69BAE1C6EEDQ48155329-D1989774-4932-44DE-B711-2F8AC8D21213Q49932201-24791F1D-2EFA-45D1-A6DC-24EFFD8C877FQ51049052-4460B4E1-9E8E-48FD-872C-B1980362D137Q51517581-EC2E4634-C814-4DA0-BB2B-58AFBE81B198Q52592095-2F8ACE00-469E-40A5-8693-E299EC20BCA2Q52668185-2A6FDC50-E700-4A42-A10E-6DD8CA5207FAQ52682124-6223A577-22AE-477A-818C-EADD470B485D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VEGF-VEGFR Signals in Health and Disease.
@en
VEGF-VEGFR Signals in Health and Disease.
@nl
type
label
VEGF-VEGFR Signals in Health and Disease.
@en
VEGF-VEGFR Signals in Health and Disease.
@nl
prefLabel
VEGF-VEGFR Signals in Health and Disease.
@en
VEGF-VEGFR Signals in Health and Disease.
@nl
P2860
P1476
VEGF-VEGFR Signals in Health and Disease.
@en
P2093
Masabumi Shibuya
P2860
P356
10.4062/BIOMOLTHER.2013.113
P577
2014-01-01T00:00:00Z